John P. DeVincenzo

John P. DeVincenzo

Auto-generated profile, based on publicly available information

John P. DeVincenzo

Enanta Pharmaceuticals, Inc. Watertown Massachusetts USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in Vaccine
Verified
Journal Article
Open access
BJBart G. Jones
Bart G. Jones
RSRobert E. Sealy
Robert E. Sealy
SSSherri L. Surman
Sherri L. Surman
APAllen Portner
Allen Portner
CRCharles Russell
Charles Russell
JHJulia Hurwitz
Julia Hurwitz
Respiratory syncytial virus (RSV) is the cause of significant morbidity and mortality among infants, and despite decades of research there remains no licensed vaccine. SeVRSV is a Sendai virus (SeV)-based live intranasal vaccine that expresses the full length RSV fusion (F) gene. SeV is the murine counterpart of human parainfluenza virus type 1. Given that the target population of SeVRSV is young infants, we questioned whether maternal antibodies typical of this age group would inhibit SeVRSV vaccine efficacy. After measuring SeV- and RSV-specific serum neutralizing antibody titers in human infants, we matched these defined titers in cotton rats by the passive transfer of polyclonal or monoclonal antibody products. Animals were then vaccinated with SeVRSV followed by a 3 month rest period to allow passively transferred antibodies to wane. Animals were finally challenged with RSV to measure the de novo vaccine-induced immune responses. Despite the presence of passively-transferred serum neutralizing antibodies at the time of vaccination, SeVRSV induced immune responses that were protective against RSV challenge. The data encourage advancement of SeVRSV as a candidate vaccine for the protection of children from morbidity and mortality caused by RSV.

1 May 2013 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
JDJ.P. DeVincenzo
J.P. DeVincenzo
CGCliff Guyton
Cliff Guyton
HRHarrison Rea
Harrison Rea
EEEvan Elmore
Evan Elmore
SPShivam Patel
Shivam Patel
BBBindiya Bagga
Bindiya Bagga

28 April 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
KEKimberly Elmore
Kimberly Elmore
JDJohn DeVincenzo
John DeVincenzo
MRMichael H. J. Rhodin
Michael H. J. Rhodin
SRScott T. Rottinghaus
Scott T. Rottinghaus
AAAlaa Ahmad
Alaa Ahmad
Respiratory syncytial virus (RSV) remains a significant health concern, particularly for vulnerable populations. Despite preventive strategies, there remains a need for effective antiviral treatments. EDP‐323 is a first‐in‐class, potent oral selective non‐nucleoside inhibitor of the large protein (L polymerase) of RSV under investigation for the treatment of RSV infection. This phase 1, randomized, double‐blind, placebo‐controlled study evaluated the safety and pharmacokinetics of EDP‐323. This study included fasted single ascending dose (SAD; EDP‐323 50/100/200/400/600/800 mg doses, 3:1 to placebo), fed multiple ascending dose (MAD; EDP‐323200/400/600/800 mg doses, 3:1 to placebo), and food effect (EDP‐323200 mg dose, 4:1 to placebo) cohorts in healthy adult participants. Key objectives were to assess the safety, tolerability, and pharmacokinetic (PK) profile of EDP‐323 in plasma and urine, and to evaluate the effect of food intake on its pharmacokinetics. Among 82 randomized participants (SAD, n = 50; MAD, n = 32), EDP‐323 was well tolerated up to the highest tested dose (800 mg once daily for 7 days). Adverse events (AEs) were reported in 14.6% of total participants, with the majority being mild and deemed unlikely related to the study drug. Headache was the most frequent AE (n = 3). PK analysis showed that EDP‐323 was rapidly absorbed (Tmax = 3.0–5.0 h), with exposures increasing with ascending dose. The half‐life of EDP‐323 (t1/2 = 10.8–16.6 h) supported once‐daily dosing, and no food effect was observed. EDP‐323 demonstrated a favorable safety and PK profile, supporting its potential as a once‐daily oral treatment for RSV.

1 March 2017 in Pediatrics
Verified
Journal Article
Open access
PDF file
TBThomas G. Boyce
Thomas G. Boyce
RYRam Yogev
Ram Yogev
JDJohn P. DeVincenzo
John P. DeVincenzo
LKLeonard R. Krilov
Leonard R. Krilov
The study by Farber et al1 on the retrospective effectiveness of palivizumab for late preterm infants contains critical design flaws that call into question many of its conclusions. The study is a retrospective cohort study of infants born at 29 to 36 weeks’ gestation from 9 Texas Medicaid managed care programs. The study was funded by managed care organizations with a financial interest in justifying cost reductions associated with palivizumab approvals. Among infants born at 29 to 32 weeks’ gestation, those with ≥1 insurance claim for palivizumab had a 38% lower rate of hospitalization for respiratory syncytial virus (RSV) (5.0% vs 3.1%, P = .04). For the infants born at 33 to 36 weeks’ … E-mail: boyce.thomas{at}mayo.edu

4 April 2022
Verified
Conference Paper
Open access
MSMahdieh Shabanian
Mahdieh Shabanian
MWMarkus Wenzel
Markus Wenzel
JDJohn P. DeVincenzo
John P. DeVincenzo
SPIE Digital Library Proceedings